Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAV-011
- Development stage
- Preclinical
- Lead developer
- Cavalry Biosciences
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
CAV-011 is an engineered insulin-like growth factor 1 (IGF-1) variant protein being developed by Cavalry Biosciences for the treatment of severe corneal diseases. The molecule is specifically designed to activate the IGF-1 receptor (IGF-1R) while resisting inhibition by IGF-1 binding proteins (IGFBPs), which are naturally occurring proteins that regulate and often limit the activity of endogenous IGF-1. By overcoming this inhibition, CAV-011 aims to enhance the regenerative signaling required for corneal epithelial repair. The drug is currently in IND-enabling development as a topical ophthalmic solution for indications including neurotrophic keratitis (NK), limbal stem cell deficiency (LSCD), and persistent corneal epithelial defects (PCED).
- Other names
- engineered IGF-1 variant
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)IGFBP5 (Insulin-like growth factor-binding protein 5)Insulin receptor/Insulin-like growth factor 1 receptor hybrid receptor (IR/IGF-1R hybrid receptor)
Beyond the preview
Go deeper on CAV-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAV-011.